Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.

IF 2.7 4区医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI:10.1080/1750743X.2024.2353539

Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji

{"title":"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.","authors":"Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji","doi":"10.1080/1750743X.2024.2353539","DOIUrl":null,"url":null,"abstract":"Aim: Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.Materials & methods: In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.Results: A*26:01, DPA1*01:03 and DPB1*02:01 were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [p = 0.004], 80.0 vs 45.2% [p = 0.020] and 55.0 vs 25.8% [p = 0.044], respectively).Conclusion: A*26:01, DPA1*01:03 and DPB1*02:01 appear to be associated with thyroid irAE.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"723-732"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2353539","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.Materials & methods: In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.Results: A*26:01, DPA1*01:03 and DPB1*02:01 were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [p = 0.004], 80.0 vs 45.2% [p = 0.020] and 55.0 vs 25.8% [p = 0.044], respectively).Conclusion: A*26:01, DPA1*01:03 and DPB1*02:01 appear to be associated with thyroid irAE.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

特异性人类白细胞抗原等位基因与甲状腺免疫相关不良事件发生之间的关系。

目的：流行病学发现，人类白细胞抗原（HLA）等位基因的固有变异会影响自身免疫性疾病的发生。因此，HLA等位基因也可能与免疫相关不良事件（irAE）的发生有关，如甲状腺irAE。材料与方法：在这项病例对照研究中，共招募了71名接受免疫检查点抑制剂治疗的癌症患者，对他们进行了HLA基因分型，并比较了HLA等位基因的频率。结果显示甲状腺irAE患者中A*26:01、DPA1*01:03和DPB1*02:01的频率明显高于无irAE患者（分别为35.0 vs 3.2% [p = 0.004]、80.0 vs 45.2% [p = 0.020]和55.0 vs 25.8% [p = 0.044]）。结论A*26:01、DPA1*01:03和DPB1*02:01似乎与甲状腺虹膜异位症有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.